Pre-made Mosunetuzumab biosimilar ( Bispecific mAb, anti-CD3E;MS4A1 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-356
Anti-CD3E;MS4A1 therapeutic antibody (Pre-made Mosunetuzumab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD3E;MS4A1 therapeutic antibody (Pre-made Mosunetuzumab biosimilar,Bispecific mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;4k7p:YX|
|Conditions Active||Diffuse large B cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Follicular lymphoma|